Genmab

News

Genmab and AbbVie prep filings for lymphoma bispecific

Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to regulators about filing for approval of the lead dr

News

FDA clears Seagen, Genmab's Tivdak ADC for cervical cancer

Antibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from the FDA for Tivdak as a second-line monotherapy for recurrent or meta

R&D

Kantar Health's Biotech Insights podcast with Genmab

Biotech Insight podcast: Overcoming planning challenges in o...

The first episode of Kantar Health’s new Biotech Insight podcast takes aim at the planning and forecasting challenges that biotechnology companies face, with a particular focus on oncology.

News

Genmab takes aims at immuno-oncology antibody conjugates wit...

Genmab has enlisted the help of Bolt Biotherapeutics to develop a new class of immune-boosting antibody conjugates for cancer in a deal that could be worth up to $880 million.

Views & Analysis

Jan van de Winkel: Building Europe’s biotech powerhouse at G...

Jan van de Winkel has overseen one of biotech’s big success stories since he took over Genmab’s CEO in 2010.

News

Genmab CEO discusses repurposing cancer treatments

Genmab’s CEO Jan van de Winkel has said he would consider spinning out a smaller autoimmune diseases biotech, while ruling out any interest in a merger with big pharma.

Genmab and AbbVie prep filings for lymphoma bispecific

FDA clears Seagen, Genmab's Tivdak ADC for cervical cancer

Biotech Insight podcast: Overcoming planning challenges in o...

Genmab takes aims at immuno-oncology antibody conjugates wit...

Jan van de Winkel: Building Europe’s biotech powerhouse at G...

Genmab CEO discusses repurposing cancer treatments

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Genmab

Editor's Picks